Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 482% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 11.2% — below-average profitability
- Revenue growing at 17% annually
Penumbra, Inc. (PEN) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $13.2 billion . Key value metrics: P/E ratio 82.4, P/B ratio 9.23, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Penumbra, Inc. — Fundamental Analysis Summary
Penumbra, Inc. (PEN) is currently trading 482% above its Graham Number of $57.75, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 82.4x.
On financial health, PEN shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 11.2% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.28.
StockPik's composite Value Score for PEN is 54/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PEN reports a high gross margin of 66.7% (sector average: 33.5%) and a solid operating margin of 12.5%.
PEN shows revenue growing at 17% year-over-year, with earnings growing at 1,168%.